Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?

Table 1 Baseline demographic, endoscopic and histological characteristics of patients

	Group 1 (n = 68) OAC 7-d	Group 2 (n = 68) OAC 10-d	P
Age (yr, mean ± SD)	42 ± 11	44 ± 12	NS
Sex (M/F)	23/45	27/41	NS
Endoscopic findings:
Normal	9	10	NS
Gastritis (IM)	31 (4)	38 (6)	NS
Gastric ulcer (IM)	13 (1)	9 (2)	NS
Duodenal ulcer (IM)	15 (0)	11 (4)	NS
Histological findings:
Nonatrophic chronic active gastritis (IM)	60	56	NS
Atrophic chronic active gastritis (IM)	8 (5)	12 (12)	NS

IM: Intestinal metaplasia; M: Male; F: Female; NS: Not significant; OAC: Omeprazole, amoxicillin and clarithromycin.

Table 2 Per protocol analysis, control results at wk 8 in two groups (%)

	Group 1 (n = 65) OAC 7-d	Group 2 (n = 52) OAC 10-d	P
H pylori eradication	44/65 (68)	46/52 (88)	0.008
Normal endoscopy	37/65 (56.9)	32/52 (63.5)	NS
Inflammatory inactivation of gastric mucosa	45/65 (69)	49/52 (96)	0.0002

OAC: Omeprazole, amoxicillin and clarithromycin; NS: Not significant.

Table 3 Intention to treat analysis, control results at wk 8 in two groups (%)

	Group 1 (n = 65) OAC 7-d	Group 2 (n = 62) OAC 10-d	P
H pylori eradication	44/65 (68)	52/62 (83.8)	0.03
Normal endoscopy	37/65 (56.9)	37/62 (61.2)	NS
Inflammatory inactivation of gastric mucosa	45/65 (69)	54/62 (88.7)	0.007

OAC: Omeprazole, amoxicillin and clarithromycin; NS: Not significant.